Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2020
Reporting Period: Specific event date (October 15, 2020)
This filing reports the entry into a material definitive agreement regarding the settlement of contingent consideration obligations from a prior acquisition.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity) for the reporting period. The only specific financial figures disclosed relate to the settlement agreement:
- Lump Sum Payment: $100,000 paid to Gregory Lucas.
- Original Acquisition Consideration (2018): $750,000 cash plus approximately $8,000 debt repayment.
- Original Contingent Consideration Cap: Up to $2,625,000 based on net revenue targets.
Material Changes
The primary material change is the termination of the Company's obligation to make future contingent consideration payments to Gregory Lucas regarding the 2018 acquisition of Biocon 1, LLC and Aether Water Systems, LLC.
- Agreement Modification: The Second Amendment to the Membership Interest Purchase Agreement (MIPA) replaces the revenue-based contingent payment structure with a fixed lump sum.
- Settlement: Upon payment of the $100,000 lump sum, the contingent consideration obligation is deemed fully satisfied.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the Second MIPA Amendment to resolve outstanding contingent liabilities. No forward-looking guidance, revenue outlook, or strategic commentary is provided in this document.
Risks and Contingencies: The filing eliminates the contingency of future payments tied to the net revenue performance of Biocon and Aether for the 2019 and 2020 fiscal years (and the extended quarter ending March 31, 2021).
Investor Verification Checklist
- Verify the cash impact of the $100,000 lump sum payment on the Company's current liquidity position.
- Confirm the full text of the Second MIPA Amendment (Exhibit 10.1) for any non-monetary terms or release of claims.
- Review prior filings to understand the revenue performance of Biocon and Aether that led to this settlement.
- Check subsequent filings for any other outstanding contingent liabilities related to the 2018 acquisition.